American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis

Arthritis Care and Research

Volumn 63, Issue 7, 2011, Pages 929-936

  Wallace, Carol A ^a   Giannini, Edward H ^b   Huang, Bin ^b   Itert, Lukasz ^b   Ruperto, Nicolino ^c   Abramson, L ^d   Bowyer, S ^d   Chalom, B ^d   Cron, R ^d   Elder, M ^d   Gewanter, H ^d   Ilowite, N ^d   Jung, L ^d   Kimura, Y ^d   Kingsbury, D ^d   Lindsley, C ^d   Lovell, D ^d   McCurdy, D ^d   Moore, R ^d   O'Neil K ^d   Rider, L ^d   Rose, C ^d   Schickler, K ^d   Sherry, D ^d   Soep, J ^d   Stein, L ^d   Vehe, R ^d   Wagner Weiner, L ^d   Zemel, L ^d   Lang, B ^d   Laxer, R ^d   Schneider, R ^d   Tucker, L ^d   Al Mayouf, S ^d   Andersson Gare, B ^d   Avcin, T ^d   Flato, B ^d   Cimaz, R ^d   De Benedetti, F ^d   Fantini, F ^d   Martini, A ^d   Ravelli, A ^d   De Cunto, C ^d   Garay, S ^d   Saad Magalhaes, C ^d   Oliveira, S ^d   De Inocencio, J ^d   Dolezalova, P ^d   Foell, D ^d   Horneff, G ^d   Melo Gomes, J ^d   Nielsen, S ^d   Ozdogan, H ^d   Ozen, S ^d   Quartier, P ^d   Kanakoudi Tsakalidou, F ^d   Uziel, Y ^d   Vesely, R ^d   Wulffraat, N ^d   more..

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c G GASLINI INSTITUTE   (Italy)

^d NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHOTREXATE;

CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL INACTIVE DISEASE; CONTENT VALIDITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FACE; HUMAN; JOINT; JOINT STIFFNESS; JUVENILE RHEUMATOID ARTHRITIS; MEDICAL EXPERT; PATIENT SELECTION; PEDIATRICS; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; RHEUMATOLOGY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; UVEITIS;

EID: 80051741699     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20497     Document Type: Review

References (32)

1. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al, for the Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9. (Pubitemid 30151920)
2. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al, for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticularcourse juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-106. (Pubitemid 47502757)
3. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al, for the Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504. (Pubitemid 351705939)
4. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al, for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20.
5. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al, for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91.
6. Raine R, Sanderson C, Hutchings A, Carter S, Larkin K, Black N. An experimental study of determinants of group judgments in clinical guideline development. Lancet 2004;364:429-37. (Pubitemid 39036890)
7. Bowles N. The Delphi technique. Nurs Stand 1999;13:32-6.
8. Horton JN. Nominal group technique: a method of decisionmaking by committee. Anaesthesia 1980;35:811-4. (Pubitemid 10018753)
9. Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4. (Pubitemid 39453253)
10. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for outcome measures in rheumatology [editorial]. J Rheumatol 1998;25:198-9.
11. Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005;52:3554-62. (Pubitemid 41612224)
12. Wallace CA, Ravelli A, Huang B, Giannini EH. Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis. J Rheumatol 2006;33:789-95.
13. Oen K. Long-term outcomes and predictors of outcomes for patients with juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol 2002;16:347-60.
14. Fantini F, Gerloni V, Gattinara M, Cimaz R, Arnoldi C, Lupi E. Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup. J Rheumatol 2003;30:579-84. (Pubitemid 36301953)
15. Flato B, Lien G, Smerdel A, Vinje O, Dale K, Johnston V, et al. Prognostic factors in juvenile rheumatoid arthritis: a casecontrol study revealing early predictors and outcome after 14.9 years. J Rheumatol 2003;30:386-93. (Pubitemid 36152609)
16. Knowlton N, Jiang K, Frank MB, Aggarwal A, Wallace C, McKee R, et al. The meaning of clinical remission in polyarticular juvenile idiopathic arthritis: gene expression profiling in peripheral blood mononuclear cells identifies distinct disease states. Arthritis Rheum 2009;60:892-900.
17. Classification and Response Criteria Subcommittee of the American College of Rheumatology Committee on Quality Measures. Development of classification and response criteria for rheumatic diseases [editorial]. Arthritis Rheum 2006;55:348-52.
18. Bombardier C, Tugwell P. A methodological framework to develop and select indices for clinical trials: statistical and judgmental approaches. J Rheumatol 1982;9:753-7.
19. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
20. Magni-Manzoni S, Ruperto N, Pistorio A, Sala E, Solari N, Palmisani E, et al. Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 2008;59:1120-7.
21. Ruperto N, Ravelli A, Oliveira S, Alessio M, Mihaylova D, Pasic S, et al, for the Pediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the definition of improvement. Arthritis Rheum 2006;55:355-63. (Pubitemid 43887020)
22. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9. (Pubitemid 27430130)
23. Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al, for the International Myositis Assessment and Clinical Studies Group. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004;50:2281-90. (Pubitemid 38924407)
24. Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, et al. Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 2008;67:703-9. (Pubitemid 351571937)
25. Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull 1971;76:378-82.
26. Davies EH, Surtees R, DeVile C, Schoon I, Vellodi A. A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease. J Inherit Metab Dis 2007;30:768-82. (Pubitemid 47559890)
27. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74. (Pubitemid 8054849)
28. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 2005;140:509-16. (Pubitemid 41224845)
29. Cassidy JT, Levinson JE, Brewer EJ Jr. The development of classification criteria for children with juvenile rheumatoid arthritis. Bull Rheum Dis 1989;38:1-7. (Pubitemid 20086833)
30. Van Tuyl LH, Vlad SC, Felson DT, Wells G, Boers M. Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference. Arthritis Rheum 2009;61:704-10.
31. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573-86.
32. Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J, et al, for the Paediatric Rheumatology International Trials Organization (PRINTO). Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010;303:1266-73.